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Abstract
The dose, volume, and clinical outcome data for penile bulb are reviewed for patients treated with 
external-beam radiotherapy. Most, but not all, studies find an association between impotence and 
dosimetric parameters (e.g., threshold doses) and clinical factors (e.g., age, comorbid diseases). 
According to the data available, it is prudent to keep the mean dose to 95% of the penile bulb 
volume to <50 Gy. It may also be prudent to limit the D70 and D90 to 70 Gy and 50 Gy, 
respectively, but coverage of the planning target volume should not be compromised. It is 
acknowledged that the penile bulb may not be the critical component of the erectile apparatus, but 
it seems to be a surrogate for yet to be determined structure(s) critical for erectile function for at 
least some techniques.
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Clinical Significance
Erectile dysfunction (ED), the consistent inability to attain or maintain an erection of 
sufficient quality to permit satisfactory sexual intercourse, is a common complication 
resulting from radiotherapy (RT) for prostate cancer (1). Many patients choose RT for their 
clinically localized prostate cancer because they believe there may be a lower risk of ED 
compared with radical prostatectomy (RP); however, this remains controversial. 
Posttreatment ED rates have been reported to be approximately 24% (brachytherapy alone), 
40% (brachytherapy plus external RT), 45% (external RT alone), 66% (nerve-sparing RP), 
75% (non–nerve-sparing RP), and 87% for cryosurgery, but physician-reported rates are 
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known to be less reliable than patient-reported outcomes, so the optimal comparison studies 
have yet to be done (2).
Endpoints
The time course for RT-associated ED is variable (reported as days to years) and often 
evolves gradually. Ascribing ED to RT alone is difficult because men lose some erectile 
function with age, and other common diseases (e.g., diabetes, hypertension) may contribute. 
Various self-administered questionnaires have been used to assess erectile function in 
clinical studies (e.g., the International Index of Erectile Function [IIEF]) (3). Additional 
objective diagnostic tests can be performed (e.g., nocturnal penile tumescence, 
somatosensory evoked potentials, bulbocavernous reflex latency, penile electromyography, 
color duplex Doppler ultrasound, dynamic infusion cavernosometry, and pharmacotesting), 
but these are generally applied to establish the etiology of ED (4).
Challenges Defining Volume
The anatomy of the pelvic floor is challenging to visualize on CT or MRI, and hence 
definition of the penile bulb (PB) varies. This may contribute to inconsistent reports (5–15). 
The PB appears as an oval-shaped, hyperintense midline structure on T2-weighted MR 
images; on axial CT imaging it is bounded by the crura, corpora spongiosum, and the levator 
ani muscle (Fig. 1; see ref. 16 for details). At University of California-San Francisco, the 
bulb is defined as the most proximal portion of the penis sitting immediately caudal to the 
prostate. We also recognize that the bulb itself is not part of the erectile apparatus but 
consider it an anatomic surrogate for periprostatic tissue likely to receive high doses of RT.
Review of Dose–Volume Data
Published studies assessing the correlations between the dose of external-beam RT, the PB 
volume irradiated, clinical factors, and ED are summarized in Table 1. Figure 2 shows a 
summary of PB dose–volume data vs. rates of ED. Studies that reported an association 
between RT dose and ED suggested that a dose of approximately 50 Gy to essentially the 
entire PB was a threshold dose for an increased risk of ED. However, several studies did not 
identify an association between RT dose and ED (5, 11, 13).
In general, it is difficult to extract a definite conclusion from these results, owing to 
relatively small numbers of patients, different anatomic definitions and endpoints for 
defining ED, and some potential methodologic problems. For example, Selek et al. (11) 
reported that 10 of 28 patients were completely impotent after RT (zero function on a 5-
point scale) but that most of these were hypertensive. Furthermore, their choice of 0 on their 
scale to define an event may not be appropriately sensitive. The most widely accepted scale 
for evaluating sexual function is the IIEF (which spans from 0 to 25). The original IIEF, 
described by Rosen et al. (3), included 15 items and five domains. They subsequently 
developed an abridged version of the questionnaire that contained five questions, and the 
scores ranged from 5 to 25 (17).
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In the 1999 report the authors found that 21 was the optimal cutoff score. Thus, whenever 
possible investigators are encouraged to use this cutoff to define ED instead of the mild, 
moderate, and severe categories (unless independently validated). Thus for example, in the 
case of the report by Selek et al. (11) it is likely than only assigning patients with a score “0” 
as being impotent underestimated the true baseline level of ED in their study population (see 
recommendations in “Toxicity Scoring”).
In addition, several of these studies included a sizable fraction of patients who received 
phosphodiesterase type 5 inhibitors that might attenuate the effects of RT on sexual function 
(18, 19). Earlier studies were less likely to be contaminated by this issue because these 
agents were not available when most of these patients were treated (7, 10).
Brown et al. (5) studied 32 patients and noted no dose–response association for ED. 
However, they used intensity-modulated RT and attempted to spare the PB, resulting in a 
mean dose to the bulb of only 25 Gy. Thus, their data do not explicitly refute the presence of 
a dose–response association at higher doses.
Several studies reported a significant dose–volume effect correlated with risk of ED using 
the metrics of Dx (i.e., the minimum dose received by x% volume of the PB). For example, 
Fisch et al. (7) noted ED in 0, 80%, or 100% of patients with a D70 of 0–40, 40–70, and >70 
Gy, respectively. Similarly, Mangar et al. (8) reported that a D90 ≥50 Gy is associated with 
a significant risk of ED. Wernicke et al. (14) reported that D30, D45, D60, and D75 
correlated with an increased risk of ED. Roach et al. (10) reported a significant correlation 
between a median PB dose of 52.5 Gy and an increase in ED. Brachytherapy studies are 
mixed in their support for an association between PB doses and ED. Merrick et al. (20) used 
a matched-pair study of ED after brachytherapy and related PB dose–volume metrics to 
patient-reported questionnaire data. The rate of ED was associated with doses to the PB 
(particularly median dose [D50]) and to a lesser degree the crura. On the other hand, the 
Macdonald et al. (21) review of 342 patients after brachytherapy failed to show an 
association between median PB dose and ED.
Factors Affecting Risk
Patient-related factors for ED have not been emphasized, except for a few reports. Post-RT 
ED rates have been reported to be higher with baseline pretreatment ED, diabetes, smoking 
history, or a history of hypertension (5, 7, 20, 22). The data, however, are somewhat 
conflicting (Table 1).
Mathematic/Biologic Models
Penile bulb dose–volume parameters may be associated with the incidence of ED, although 
the results are conflicting to prove a clear correlation between those parameters (Fig. 2). For 
example, van der Wielen et al. (23) reviewed the literature and concluded that “sparing of 
the penile bulb to improve potency-preservation is not sufficiently supported by the current 
literature…” and questioned whether the potential “oncological risk” was justified given the 
uncertainty of potency sparing. It is possible that the key anatomic structures involved in ED 
pathophysiology have not been defined. Moreover, dosimetric accuracy of the true 
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accumulated dose distribution has seldom been examined in detail. The data are sparse. 
Overall, the data plotted in Fig. 2 may be consistent with either a causal or surrogate 
relationship.
Special Situations
Hormonal therapy itself is associated with the ED. Several studies reported the deleterious 
impact of hormonal therapy on erectile function (3, 17, 23–27). However, the association of 
hormonal therapy with RT dose/volume of the PB is unknown.
Recommended Dose/Volume Limits
On the basis of the data available, it is prudent to keep the mean dose to 95% of the PB 
volume to <50 Gy. It may also be prudent to limit the D70 and D90 to 70 Gy and 50 Gy, 
respectively. It is acknowledged that the PB may not be the critical component of the 
erectile apparatus, but it seems to be a surrogate for yet to be determined structure(s) critical 
for erectile function for at least some techniques.
Future Toxicity Studies
Standard methods to define the PB and associated critical structures should become more 
widely used. A standard method to score ED should be more widely adopted. Systematic 
prospective clinical trials that attempt to relate the three-dimensional dose–volume 
parameters from all of the potentially critical structures to clinical outcomes should be 
considered. Such studies may help to identify which pelvic structures are critical for ED. 
Dosimetric/imaging studies estimating uncertainties in the overall accumulated “true dose 
distribution” should be considered. This may be a key cause of inconsistencies between 
reported results. Anatomic studies to better define the critical anatomic sites for RT-
associated ED may be helpful. Well-characterized data (including full dose distribution and 
imaging information) should be pooled from multiple studies where possible.
Toxicity Scoring
We recommend that patients undergo pre- and post-RT assessment of ED using the IIEF. 
Patients can be grouped into five groups according to their scores; for example, in none (25–
22), mild (21–17), mild to moderate (16–12), moderate (11–8), and severe (7–5). It is 
important that the evaluation of ED is performed with a detailed history including sexual, 
medical, and psychosocial status and other laboratory tests (3, 17, 26, 27). Further clinical 
studies may be needed to validate the IIEF for the assessment of ED after RT.
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Penile and erectile tissue anatomy with CT (A) and MR (B–D) images of the penile bulb (*). 
Adapted from Wallner et al. (16).
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Incidence of erectile dysfunction according to the radiation dose to the penile bulb. The x 
axis values are estimated according to the range of doses reported. The data for Fisch et al. 
(7) at 20, 55, and 80 Gy represent the reported rates of erectile dysfunction at <40, 40–70, 
and >70 Gy, respectively. Similarly, for Wernicke et al. (14) and Roach et al. (10), each 
symbol represents the rates of erectile dysfunction at ≤42 vs. >42 and <52.5 vs. ≥52.5 Gy, 
respectively. The dashed horizontal lines reflect the dose ranges ascribed to each data point. 
The upper x-axis range of the highest data point for Fisch et al. (7) and Roach et al. (10) are 
unknown. The mean doses of van der Wielen et al. (13) and Mangar et al. (8) are estimated 
from the subgroup data. The x-axis values for Wernicke et al. (14) are D60 and for Fisch et 
al. (7) are D70 (i.e., minimum dose received by 60% or 70% volume of the penile bulb). A 
thick solid line represents the fitted model with sample size correction, with 95% confidence 
intervals (dotted curves).
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